Natural Albumin Segment, by End User to Account Largest Share in Albumin Market during 2025-2031

According to our new research study on "Albumin Market Forecast to 2031 - Global Analysis - by Source, Application, and End User," the market was valued at US$ 6.06 billion in 2024 to US$ 9.22 billion by 2031; the market is expected to register a CAGR of 6.3% during 2025-2031. The albumin market growth is attributed to the rising prevalence of chronic diseases, advancements in biotechnology, and soaring demand in biopharmaceuticals.

According to the World Health Organization (WHO), chronic diseases-including cardiovascular disease, cancer, diabetes, and respiratory illnesses-are expected to account for 86% of global deaths by 2050, representing a 90% increase since 2019. This rise is driven by factors such as aging populations, lifestyle shifts, and growing obesity rates. A recent UNICEF report from September 2025 reveals that childhood and adolescent obesity has tripled since 2000, now impacting ~188 million young people worldwide.

According to the Centers for Disease Control and Prevention's (CDC's) Behavioral Risk Factor Surveillance System, in 2023, 76.4% of US adults had at least one chronic condition, while 51.4% were affected by multiple conditions. This increasing trend demonstrates the need for medical interventions, such as albumin-based treatments. Albumin is crucial in controlling hypoalbuminemia, a frequent complication of chronic liver disease and nephrotic syndrome. Further, its administration for fluid resuscitation in burns highlights its value in critical care and emergency medicine.

Based on source, the albumin market is divided into natural and recombinant albumin. In 2024, the natural albumin segment held a significant share. Natural albumin leads the market because of its proven safety, wide range of therapeutic uses, and well-established production methods. It is made from human plasma and is vital for critical care treatments such as hypoalbuminemia and burns, maintaining steady demand in hospitals and clinics around the world. Natural albumin is further classified into human serum albumin, bovine serum albumin, and plant serum albumin.

Based on application, the albumin market is divided into therapeutic applications, drug delivery, disease diagnostics, research, and others. The therapeutic applications segment held a significant share in 2024. Therapeutic applications, including treatment of liver and kidney diseases, surgery support, hypovolemia, and hypoalbuminemia, drive the albumin market by creating consistent demand. Albumin maintains blood volume and balances plasma proteins, making it essential in critical care and surgical settings. Its therapeutic uses are divided into liver and kidney diseases, surgery, hypovolemia and hypoalbuminemia, and other conditions.

Based on end user, the albumin market is categorized into hospitals and clinics, pharmaceutical and biotechnological companies, research institutes, diagnostic laboratories, home care settings, and others. The hospitals and clinics segment held a significant albumin market share in 2024. Hospitals and clinics are the main users of albumin because of their high demand in emergency care, surgeries, and managing chronic diseases. Albumin is used for fluid replacement, protein restoration, and other treatments. Albumin is steadily consumed, highlighting its important role in the healthcare systems.

CSL Ltd, Grifols SA, Taibang Bio Group Co. Ltd., Merck KGaA, Octapharma AG, HiMedia Laboratories Pvt Ltd, Takeda Pharmaceutical Co Ltd, Thermo Fisher Scientific Inc, InVitria, Biotest AG., Medxbio Pte Ltd, Lazuline Biotech Private Limited, Cyagen Biosciences, Sartorius AG, Aspira Chemical, Lee BioSolutions, Reliance Life Sciences Private Limited, Kedrion SpA, Biorbyt Ltd., Akron Biotech are among the leading companies operating in the global Albumin market.

Companies operating in the albumin market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the albumin market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall albumin market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com